Bassam Yaghmour, MD
Critical Care Medicine · Orange, CANPI 1710117288
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $293,768 of the $376,256 with a category attached, or 78.1%. 11 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 46.1% of the total. Among critical care medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $1019.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$174K
- Bayer$97K
- Merck$66K
- United Therapeutics Corporation$39K
- GSK$162
- Inari Medical, Inc.$152
- plus $184 from 5 others
Across 128 payments — averaging $31,486 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3.5M
- United Therapeutics Corporation$377K
- Bayer$99K
- Pfizer$32K
- Novartis$909
What the payments were for
- Consulting fees$46,47212%
- Speaking & faculty fees$293,76878%
- Travel & lodging$25,5137%
- Food & beverage$10,5033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 159 | $173,642 |
| Bayer | 97 | $96,639 |
| Merck | 48 | $66,006 |
| United Therapeutics Corporation | 51 | $39,472 |
| GSK | 6 | $162 |
| Inari Medical, Inc. | 2 | $152 |
| E.r. Squibb & Sons, L.L.C. | 1 | $81 |
| Boehringer Ingelheim | 2 | $56 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $17 |
| Johnson & Johnson | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$149,034
- OPSUMIT$146,339
- Adempas$90,788
- WINREVAIR$59,915
- ORENITRAM$26,778
- TYVASO$21,449
- REMODULIN$20,579
- NONE$2,900
- FLOWTRIEVER CATHETER, S$129
- CT THROMBECTOMY SYSTEM KIT$129
How this compares
$376,256 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 39 | $841,745 |
| OpsumitMacitentan | 70 | $833,120 |
| WinrevairSotatercept-Csrk | 27 | $419,587 |
| AdempasRiociguat | 17 | $263,261 |
| OpsynviMacitentan/Tadalafil | 14 | $167,994 |
| Ambrisentan | 39 | $155,100 |
| AdcircaTadalafil | 15 | $63,247 |
| Sildenafil Citrate | 67 | $28,479 |
| Tadalafil | 36 | $23,346 |
| EliquisApixaban | 14 | $12,792 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $10,238 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $2,315 |
| Ventolin HfaAlbuterol Sulfate | 12 | $638 |
| Furosemide | 31 | $182 |
| Spironolactone | 28 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Opsynvi | $173,642 | $1,842,859123 claims |
| MerckWinrevair | $66,006 | $419,58727 claims |
| BayerAdempas | $96,639 | $263,26117 claims |
| United Therapeutics CorporationAdcirca | $39,472 | $63,24715 claims |
| GSKTrelegy Ellipta | $162 | $10,23819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Orange
- Huawei DongOrange$44K
- Timmy ChengOrange$16K
- Shahid HayatOrange$13K
- Lillian ChowOrange$11K
- Amir GhiassiOrange$10K
- Cedric Franklin RutlandRiverside$3.2M
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Stephen ChenMonterey Park$394K
- Xuanha WhiteSan Diego$343K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.